# AMERICAN MEDICAL SECURITY GROUP INC

Form 10-Q

November 14, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X] Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2001
OR [ ] Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934
For the transition period from to
COMMISSION FILE NUMBER 1-13154
AMERICAN MEDICAL SECURITY GROUP, INC. (Exact name of Registrant as specified in its charter)
WISCONSIN 39-1431799 (State of Incorporation) (I.R.S. Employer Identification No.)
3100 AMS BOULEVARD GREEN BAY, WISCONSIN  (Address of principal executive offices)  (Zip Code)
Registrant's telephone number, including area code: (920) 661-1111
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesX No
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common stock, no par value, outstanding as of October 31, 2001: 13,952,689 shares

AMERICAN MEDICAL SECURITY GROUP, INC.

INDEX

PART	I.	FINANCIAL INFORMATION
	Item 1.	Financial Statements (Unaudited)
		Condensed Consolidated Balance Sheets September 30, 2001 and December 31, 20003
		Condensed Consolidated Statements of Operations Three months ended September 30, 2001 and 2000; Nine months ended September 30, 2001 and 20005
		Condensed Consolidated Statements of Cash Flows Nine months ended September 30, 2001 and 20006
		Notes to Condensed Consolidated Financial Statements September 30, 2001
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations12
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk16
PART	II.	OTHER INFORMATION
	Item 1.	Legal Proceedings17
	Item 2.	Changes in Securities and Use of Proceeds18
	Item 6.	Exhibits and Reports on Form 8-K18
	Signatur	es19
	Exhibit	IndexEX-1
		2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMERICAN MEDICAL SECURITY GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

September 30, 2001 -----(IN TH

ASSETS

Investments:		
Securities available for sale, at fair value:		
Fixed maturities	\$	258 <b>,</b> 181
Equity securities-preferred		2,459
Fixed maturity securities held to maturity, at amortized cost		4,295
Trading securities, at fair value		388
Total investments		265,323
Cash and sash souisalouts		22 207
Cash and cash equivalents		23,307
Other assets:		
Property and equipment, net		32,756
Goodwill and other intangibles, net		104,841
Other assets		41,172
		·
		ļ
Total other assets		178,769
Total assets	\$	467,399
	=====	

See Notes to Condensed Consolidated Financial Statements

3

AMERICAN MEDICAL SECURITY GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

	September 30, 2001
	(IN TH
LIABILITIES AND SHAREHOLDERS' EQUITY	
Liabilities:  Medical and other benefits payable Advance premiums Payables and accrued expenses Notes payable Other liabilities	\$ 132,028 16,135 30,358 40,358 21,518
Total liabilities	240,397

Shareholders' equity:		
Common stock (no par value, \$1 stated value, 50,000,000 shares authorized,		
16,654,315 issued and 13,954,189 outstanding at September 30, 2001,		
16,654,315 issued and 14,270,945 outstanding at December 31, 2000)		16,654
Paid-in capital		187,834
Retained earnings		36,125
Accumulated other comprehensive income (loss), net of tax benefit		
(expense) of (\$2,145,000) at September 30, 2001 and \$2,126,000		
at December 31, 2000		3,984
Treasury stock (2,700,126 shares at September 30, 2001		
and 2,383,370 shares at December 31, 2000, at cost)		(17,595)
Total shareholders' equity		227,002
Total liabilities and shareholders' equity	\$	467,399
	=====	

See Notes to Condensed Consolidated Financial Statements

4

## AMERICAN MEDICAL SECURITY GROUP, INC.

# CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended September 30,						Nin S	
	2001		2000				2001	
			(IN	THO	usands,	EXCEPT	PER	SHARE
Revenues:								
Insurance premiums	\$	204,399		\$	231,9	963	\$	640,
Net investment income		4,280			4,6	520		13,
Realized investment losses		(660)				(90)		(
Other revenue		5,369			5,2	263		16,
Total revenues		213,388			241,7	756		668,
Expenses:								
Medical and other benefits		144,000			180,1	41		466,
Selling, general and administrative		61,513			61,0	060		195,
Interest expense		687			8	390		2,
Amortization of goodwill and intangibles		906			9	946		2,

Total expenses		207,106	 243,037		667 <b>,</b>
Income (loss) before income taxes		6,282	(1,281)		1,
Income tax expense		2,778	 95		1,
Net income (loss)	\$ =====	3,504 	\$ (1,376)	\$ ====	(
Net income (loss) per common share:  Basic Diluted	\$ \$	0.25 0.25	\$ (0.09) (0.09)	\$ \$	(0

See Notes to Condensed Consolidated Financial Statements

5

## AMERICAN MEDICAL SECURITY GROUP, INC.

# CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Payables and accrued expenses

	Nine Mo Septe
	 2001
	(IN T
OPERATING ACTIVITIES:	
Net income (loss)	\$ (170)
Adjustments to reconcile net income (loss) to net cash	
used in operating activities:	
Depreciation and amortization	7,757
Net realized investment losses	839
Increase in trading securities	(128)
Deferred income tax expense (benefit)	(702)
Changes in operating accounts:	
Other assets	2,186
Medical and other benefits payable	(13,282)
Advance premiums	(1,433)

4,456

Other Habilities	949
Net cash provided by (used in) operating activities	472
INVESTING ACTIVITIES:	
Purchases of available for sale securities	(87,078)
Proceeds from sale of available for sale securities	93 <b>,</b> 594
Proceeds from maturity of available for sale securities	8,030
Proceeds from maturity of held to maturity securities	_
Purchases of property and equipment	(4,349)
Proceeds from sale of property and equipment	8
Net cash provided by (used in) investing activities	10,205
FINANCING ACTIVITIES:	
Issuance of common stock	_
Purchase of treasury stock	(2,102)
Issuance of treasury stock	26
Borrowings under line of credit agreement	_
Repayment on line of credit agreement	_
Repayment of notes payable	(900)
Net cash used in financing activities	(2,976)
Cash and cash equivalents:	
Net increase (decrease)	7,701
Balance at beginning of year	15,606
Balance at end of period	\$ 23,307
	==========

See Notes to Condensed Consolidated Financial Statements

6

949

#### AMERICAN MEDICAL SECURITY GROUP, INC.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

September 30, 2001

#### NOTE A. BASIS OF PRESENTATION

Other liabilities

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2001 are not necessarily indicative of the results that may be expected for the year

ending December 31, 2001. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the American Medical Security Group, Inc. ("AMSG" or the "Company") annual report on Form 10-K for the year ended December 31, 2000.

#### NOTE B. EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per common share are computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per common share are computed by dividing net income (loss) by the weighted average number of common shares outstanding, adjusted for the effect of dilutive employee stock options.

The following table provides a reconciliation of the number of weighted average basic and diluted shares outstanding:

	Three Month Septembe	Nine Months September	
	2001	2000	2001
Weighted average common shares outstanding - basic	13,992,446	14,562,275	14,080,760
Effect of dilutive stock options	70 <b>,</b> 597	_	_
Weighted average common shares outstanding - diluted	14,063,043	14,562,275	14,080,760

The effect of dilutive securities was excluded from the diluted earnings (loss) per common share computation for the three months ended September 30, 2000 and the nine months ended September 30, 2001 because the Company had a net loss in those periods, therefore their inclusion would have been antidilutive. Certain options to purchase shares were not included in the computation of diluted earnings (loss) per common share because the options' exercise prices were greater than the average market price of the outstanding common shares for the period.

7

## NOTE C. COMPREHENSIVE INCOME

Comprehensive income is defined as net income (loss) plus or minus other comprehensive income, which for the Company, under existing accounting standards, includes unrealized gains and losses, net of income tax effects, on certain investments in debt and equity securities. Comprehensive income for the Company is calculated as follows:

Three Months Ended

Nine Months

	September 30,					September		
	2001 2		2000		2001			
		(IN THOUS			USANDS)			
Net income (loss)	\$	3,504	\$	(1,376)	\$	(170)		
Change in unrealized gain/loss on available for sale securities		4,944		2,634		7 <b>,</b> 932		
Comprehensive income	\$	8,448	\$	1 <b>,</b> 258	\$	7 <b>,</b> 762		

#### NOTE D. DEBT

At September 30, 2001, the Company maintained a revolving bank line of credit agreement ("Credit Agreement") with a maximum commitment of \$35.2 million and a \$10.0 million sublimit for swingline loans. At September 30, 2001, the outstanding balance of advances under the Credit Agreement was \$35.2 million. The Credit Agreement contains customary covenants which, among other matters, require the Company to achieve minimum financial results and restrict the Company's ability to incur additional debt, pay future cash dividends and dispose of assets outside the ordinary course of business. The Credit Agreement was amended in April 2001 to revise the Company's applicable interest rate on outstanding loans and the schedule of mandatory future commitment reductions including a \$4.8 million maximum commitment reduction from \$40.0 million to \$35.2 million on April 27, 2001. Revised future annual principal amounts due for all of the Company's debt, including debt under the Credit Agreement, as of September 30, 2001 are \$0.3 million for 2001, \$6.2 million for 2002, \$11.2 million for 2003, \$12.5 million for 2004, and \$10.2 million for 2005.

#### NOTE E. CONTINGENCIES

On August 26, 1999, a \$6.9 million verdict was entered against the Company in a lawsuit filed by Skilstaf, Inc. which principally alleged breach of contract involving the timing of claims payments. Following an adverse decision from the Court of Appeals on March 12, 2001, the Company recognized an additional accrual during the first quarter of 2001 representing the full potential loss including punitive damages and other expenses. The Company petitioned the United States Supreme Court to review the case. In July 2001, at the direction of the district court, the Company paid the full amount of the verdict plus interest. In October 2001, the United States Supreme Court denied the Company's request to review the Court of Appeals' decision. The case is now closed

On February 7, 2000, a \$5.4 million verdict was entered against the Company in a lawsuit filed by Health Administrators, Inc., an insurance agency owned and operated by a former agent of the Company, which alleged breach of contract involving commission amounts due to such agent. On March 29, 2001, the Ohio Court of Appeals affirmed a portion of the verdict, with modifications, representing approximately \$3.0 million in damages, and reversed and remanded the remaining issue in the case representing approximately \$2.4 million in damages. The Company appealed the \$3.0 million portion of the damages to the Ohio Supreme Court, which declined to take the appeal. Briefs have been submitted for the remanded portion of the case and the parties are awaiting the trial court's decision. Management believes that the Company has adequately provided for losses that may result from this case.

The Company is involved in various other legal and regulatory matters occurring in the normal course of its business. While the ultimate outcome of the legal and regulatory matters cannot be determined at this time, in the opinion of management, adequate provision has been made for losses which may result from such matters; accordingly, the outcome of these matters is not expected to have a material adverse effect on the consolidated financial statements. The Company's financial results for the nine months ended September 30, 2001 reflect a first quarter pre-tax charge of \$9.0 million (\$5.9 million after-tax) to cover estimated potential losses and related expenses for legal related matters.

#### NOTE F. NEW ACCOUNTING STANDARDS

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, BUSINESS COMBINATIONS, and No. 142, GOODWILL AND OTHER INTANGIBLE ASSETS (the "Statements"), effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill (and intangible assets deemed to have indefinite lives) will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives. Based on the Company's current accounting policy of measuring goodwill impairment based on undiscounted cash flows, there is no goodwill impairment indicated.

The Company will apply the new rules on accounting for goodwill and other intangible assets beginning in the first quarter of 2002. Application of the nonamortization provisions of the Statements is expected to result in an increase in net income of approximately \$2.4 million (\$0.17 per share) per year. The Company will perform the first of the required impairment tests of goodwill and intangible assets deemed to have indefinite lives as of January 1, 2002 by comparing the fair value of the Company's reporting units to their carrying amounts (book value), including goodwill. In determining the fair value of the Company's reporting units, management will consider valuation techniques such as the quoted market price of the Company's stock, the present value of future cash flows and market comparison of similar assets and liabilities. As of September 30, 2001, the Company's book value per share was significantly higher than the quoted market value of a share of stock. The Company has not yet determined what the effect of these tests will be on the earnings and financial position of the Company. If it is determined that an impairment exists as of January 1, 2002, the charge recognized would be reported as the cumulative effect of a change in accounting principle in the Company's consolidated financial statements and would have no impact on cash flows or the statutory basis capital and surplus of the Company's insurance subsidiaries.

#### NOTE G. SEGMENT INFORMATION

The Company has two reportable segments: 1) health insurance products, and 2) life insurance products. The Company's health insurance products consist of the following coverages related to small group preferred provider organization products: MedOne (for individuals and families) and small group medical, self funded medical, dental and short-term disability. Life products consist primarily of group term-life insurance. The "All Other" segment includes operations not directly related to the business segments and unallocated corporate items (i.e., corporate investment income, interest expense on corporate debt, amortization of goodwill and intangibles and unallocated overhead expenses). The reportable segments are managed separately because they differ in the nature of the products offered and in profit margins.

The Company evaluates segment performance based on profit or loss before income taxes, not including gains and losses on the Company's investment

portfolio. The accounting policies of the reportable segments are the same as those used to report the Company's consolidated financial statements. Intercompany transactions have been eliminated prior to reporting reportable segment information.

9

A reconciliation of segment income (loss) before income taxes to consolidated income (loss) before income taxes is as follows:

	Three Months Ended September 30,					Nine Month Septembe		
	2001 2000			2001				
				(IN THC	USANDS	)		
Health segment Life segment All other	\$	5,788 1,615 (1,121)	2,006			(1,397) 4,963 (2,192)		
Income (loss) before income taxes	\$	6,282	\$	(1,281)	\$	1,374		

Operating results and statistics for each of the Company's  $% \left( 1\right) =\left( 1\right) +\left( 1\right)$ 

	Three Months Ended September 30,				Nine Months September		
		2001				2001	
				(IN THC	USANDS	)	
HEALTH SEGMENT							
OPERATING RESULTS							
Revenues:    Insurance premium    Net investment income    Other revenue		200,256 2,299 4,370				7,014	
Total revenues		206,925		229,098		646,325	
Selling, general and administrative				57 <b>,</b> 525		185 <b>,</b> 778	
Total expenses		201 <b>,</b> 137		233,054		647 <b>,</b> 722 	
Income (loss) before income taxes	\$			(3,956)	\$ ====	(1,397)	==

## FINANCIAL STATISTICS

Loss ratio Expense ratio	71.3% 27.0%	78.8% 23.9%	73.8% 27.6%
Combined ratio	98.3%	102.7%	101.4%
Membership at End of Period:			
Health:	262 010	475 706	
Fully insured medical	363,912	475 <b>,</b> 706	
Self funded medical	45 <b>,</b> 180	54 <b>,</b> 948	
Stand-alone dental	171,214	176,727	
Total health	580,306	707,381	

(a) Total health membership for the Company of 580,316 and 714,391 at September 30, 2001 and 2000 includes HMO membership of 10 and 7,010, respectively. HMO operations are not included in health segment operating results.

10

	Three Months Ended September 30,				Nine Months September		
		2001		2000		2001	
				(IN THO	USANDS)		
LIFE SEGMENT							
OPERATING RESULTS							
REVENUES: Insurance premiums Net investment income Other revenue	\$	4,135 160 38	\$	5,460 157 57	\$	13,581 496 120	
Total revenues		4,333		5 <b>,</b> 674		14,197	
Expenses:  Medical and other benefits Selling, general and administrative  Total expenses		1,362 2,718		3,668		5,038 4,196 9,234	
Income before income taxes		1,615		2,006 ======	\$ =====	4,963	
FINANCIAL STATISTICS							
Loss ratio Expense ratio		32.8% 32.0%		38.5% 27.6%		37.1% 30.0%	

Combined ratio	64.8%	66.1%	67.1%

196,035

11

259,000

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

#### OVERVIEW

American Medical Security Group, Inc., together with its subsidiary companies ("AMSG" or the "Company"), is a provider of health care benefits and insurance products for individuals and small employer groups. The Company's principal product offerings are (1) health insurance for small employer groups and (2) health insurance for individuals and families ("MedOne"). The Company also offers life, dental, prescription drug, disability and accidental death insurance, and provides stop-loss reinsurance and benefit administration for self funded employer groups. The Company's products are actively marketed in 32 states and the District of Columbia through independent agents. The Company's products generally provide discounts to insureds that utilize preferred provider organizations ("PPOs"). AMSG owns a preferred provider network and also contracts with other networks to ensure cost-effective health care choices to its customers.

#### RESULTS OF OPERATIONS

Membership at End of Period

The Company reported net income of \$3.5 million or \$0.25 per share for the third quarter of 2001. This compares to a net loss of \$1.4 million or \$0.09 per share for the third quarter of 2000. The improvement in profitability from the third quarter of the prior year primarily reflects the results of management's strategic plan including aggressive price increases, significant growth in the Company's MedOne business and focused sales to target markets with the best possible returns. Improving performance from the Company's small group health business following several quarters of aggressive rate action necessary to counter rising claim costs also contributed to the Company's profitability.

For the nine months ended September 30, 2001, the Company reported a net loss of \$170,000 or \$0.01 per share, compared to net income of \$2.5 million or \$0.17 per share for the same period in 2000. The nine month results for 2001 reflect an after-tax charge of \$5.9 million or \$0.41 per share taken in the first quarter for legal related matters. See "Part II., Item 1. Legal Proceedings" for a detailed discussion.

Excluding the effect of the legal accrual recorded in the first quarter, the results for the third quarter of 2001 represent the fourth consecutive quarter of improved earnings for the Company. The Company's health loss ratio has declined for the fourth consecutive quarter and is at its lowest point in more than two years. Management anticipates that the trend of health loss ratio and earnings improvement will continue during the remainder of 2001. Management now anticipates earnings to be approximately \$0.65 per share for the full year of 2001, excluding the first quarter legal accrual.

#### INSURANCE PREMIUMS AND MEMBERSHIP

Insurance premiums for the three months ended September 30, 2001 decreased 11.9% to \$204.4 million from \$232.0 million for the same period in 2000. For the nine month period ended September 30, 2001, insurance premiums decreased to \$640.5 million from \$720.4 million for the same period in the prior year. The decrease primarily resulted from a decline in membership in select unprofitable small group and exited markets, partially offset by rising premium rates on the continuing block of business. Average fully insured medical premium per member per month for the third quarter of 2001 increased by 15.4% to \$158, compared to the third quarter of 2000, reflecting significant rate actions taken by the Company. As a result of the Company's actions to change its product mix, redefine its markets, increase profitability, and reposition itself for the future, quarterly insurance premiums are expected to shrink slightly before leveling out in mid-year 2002.

12

Total medical and dental membership declined from 714,391 members at September 30, 2000 to 580,316 members at September 30, 2001. The membership decrease is primarily the result of the Company's success in terminating business in several unprofitable markets, including exited markets, and lower sales due to aggressive premium rate increases. The Company's MedOne product for individuals and families continues to grow as a percentage of the Company's overall business reflecting management's strategy to change the Company's mix of business. MedOne membership now accounts for 43% of the Company's medical membership in force. At the end of 1999 and 2000, MedOne membership accounted for 23% and 34%, respectively. Management considers the MedOne product to be a key strategic product and continues to take steps to accelerate membership and premium growth in this market through an expanded agent force and additional regional and national distribution agreements.

#### NET INVESTMENT INCOME

Net investment income for the three months ended September 30, 2001 decreased to \$4.3 million from \$4.6 million for the three months ended September 30, 2000. Net investment income was \$13.2 million for the nine months ended September 30, 2001 compared to \$14.4 for the same period in 2000. The decrease in net investment income is due primarily to a decrease in average invested assets, offset partially by an increase in the average annual investment yield. Average invested assets at cost were \$264.0 million for the third quarter of 2001. In comparison, average invested assets were \$291.6 million for the third quarter of 2000. The average annual investment yield was 6.49% for the third quarter of 2001 compared to 6.34% for the third quarter of 2000. Invested assets have declined primarily as a result of the repurchase of Company stock.

## OTHER REVENUE

Other revenue, which primarily consists of administrative fee income from claims processing and other administrative services, increased to \$5.4 million for the quarter compared to \$5.3 million for the third quarter of 2000, and to \$16.1 million for the nine months ended September 30, 2001 from \$15.2 million for the same period in 2000. The increase from the prior year is primarily due to an increase in fees charged for administrative services.

#### LOSS RATIO

The health loss ratio for the third quarter of 2001 was 71.3% compared to 78.8% for the third quarter of 2000. The health loss ratio for the nine months ended September 30, 2001 was 73.8% compared to 77.4% for the nine months ended September 30, 2000. The significant improvement was due to management's actions

and strategies to increase premiums and combat medical inflation. These actions included premium rate increases, claims cost control initiatives and the exit from unprofitable small group markets. The reduction also reflects increased sales of MedOne products, which are priced for a lower loss ratio but have higher selling and administrative costs. As anticipated, claim costs per member per month have increased slightly, but were more than offset by increased premiums per member per month.

The life segment loss ratio for the three months ended September 30, 2001 was 32.8% compared to 38.5% for the three months ended September 30, 2000. The life segment loss ratio for the nine months ended September 30, 2001 was 37.1% compared with 34.3% for the nine months ended September 30, 2000. The life segment loss ratio tends to fluctuate from quarter to quarter as actual life claims experience fluctuates. The life segment loss ratio for the nine month period ended September 30, 2001 is consistent with historical averages and anticipated average future results for this segment.

13

#### SELLING, GENERAL AND ADMINISTRATIVE EXPENSE RATIO

The selling, general and administrative ("SG&A") expense ratio includes commissions and selling expenses, administrative expenses, and premium taxes and assessments. The SG&A expense ratio for health segment products for the three months ended September 30, 2001 was 27.0%. This compares to 23.9% reported for the three months ended September 30, 2000. Excluding the non-recurring legal accrual recorded during the first quarter of 2001, the SG&A expense ratio for health segment products for the nine months ended September 30, 2001 was 26.2% compared with 24.0% for the same period in 2000. The increase largely reflects a product mix change driven by growth in the MedOne business which has higher selling and administrative costs but lower claim costs than the small group product. Lower premium volume also contributed to the increase in the SG&A ratio.

### LIQUIDITY AND CAPITAL RESOURCES

The Company's sources of cash flow consist primarily of insurance premiums, administrative fee revenue and investment income. The primary uses of cash include payment of medical and other benefits, SG&A expenses and debt service costs. Positive cash flows are invested pending future payments of benefits and other operating expenses. The Company's investment policies are designed to maximize yield, preserve principal and provide liquidity to meet anticipated payment obligations.

The Company's cash provided by operations was \$0.5 million for the nine months ended September 30, 2001, including payment of the Skilstaf, Inc. judgment in the third quarter. This compares to cash used in operations of \$8.6 million for the nine months ended September 30, 2000. The improvement in cash flow primarily reflects increased profitability of the Company. Management now expects cash flow to be positive for the fourth quarter and full year of 2001.

The Company's investment portfolio consists primarily of investment grade bonds and has limited exposure to equity securities. At September 30, 2001, \$262.5 million or 98.9% of the Company's investment portfolio was invested in bonds. At December 31, 2000, \$267.0 million or 99.0% of the Company's investment portfolio was invested in bonds. The bond portfolio had an average quality rating of Aa2 at September 30, 2001 and Aa3 at December 31, 2000, as measured by Moody's Investor Service. The majority of the bond portfolio was classified as available for sale. The Company has no investment in mortgage loans,

non-publicly traded securities (except for principal only strips of U.S. Government securities), real estate held for investment or financial derivatives.

The Company's insurance subsidiaries operate in states that require certain levels of regulatory capital and surplus and may restrict dividends to their parent companies. Based upon the financial statements of the Company's insurance subsidiaries as of December 31, 2000, as filed with the insurance regulators, no dividends may be paid by these subsidiaries without prior regulatory approval.

The National Association of Insurance Commissioners has adopted risk-based capital ("RBC") standards for health and life insurers designed to evaluate the adequacy of statutory capital and surplus in relation to various business risks faced by such insurers. The RBC formula is used by state insurance regulators as an early warning tool to identify insurance companies that potentially are inadequately capitalized. At December 31, 2000, the Company's principal insurance company subsidiaries had RBC ratios that were substantially above the levels which would require regulatory action.

During 2000, the Company's Board of Directors authorized an increase to the Company's share repurchase program to a maximum allowable repurchase of \$18.0 million. The Company purchased 75,100 shares of its outstanding common stock during the third quarter of 2001 at a cost of \$456,000. During October 2001, the Company reached its maximum authorized purchase threshold, bringing the total purchased under the program to 2.7 million shares at an aggregate purchase price of \$18.0 million.

14

At September 30, 2001, the Company maintained a revolving bank line of credit agreement ("Credit Agreement") with a maximum commitment of \$35.2 million and a \$10.0 million sublimit for swingline loans. At September 30, 2001, the outstanding balance of advances under the Credit Agreement was \$35.2 million. The Credit Agreement contains customary covenants which, among other matters, require the Company to achieve minimum financial results and restrict the Company's ability to incur additional debt, pay future cash dividends and dispose of assets outside the ordinary course of business. The Credit Agreement was amended in April 2001 to revise the Company's applicable interest rate on outstanding loans and the schedule of mandatory future commitment reductions including a \$4.8 million maximum commitment reduction from \$40.0 million to \$35.2 million on April 27, 2001. Revised future annual principal amounts due for all of the Company's debt, including debt under the Credit Agreement, as of September 30, 2001 are \$0.3 million for 2001, \$6.2 million for 2002, \$11.2 million for 2003, \$12.5 million for 2004, and \$10.2 million for 2005.

## CAUTIONARY FACTORS

This report and other documents or oral presentations prepared or delivered by and on behalf of the Company contain or may contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements based upon management's expectations at the time such statements are made and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from those contemplated in the statements. Readers are cautioned not to place undue reliance on the forward-looking statements. When used in written documents or oral presentations, the terms "anticipate," "believe," "estimate," "expect," "objective," "plan," "possible," "potential," "project" and similar expressions are intended to identify forward-looking statements. In addition to the assumptions and other factors referred to specifically in connection with such

statements, factors that could cause the Company's actual results to differ materially from those contemplated in any forward-looking statements include, among others, the following:

- Unexpected increases in health care costs resulting from the aging of the population, advances in medical technology, increased utilization of medical services and prescription drugs resulting from bioterrorism or otherwise, health care inflation (particularly technology-driven procedures and drug costs), possible epidemics and natural or man-made disasters and other factors affecting the delivery and cost of health care that are beyond the Company's control.
- The Company's ability to profitably distribute and sell its products, including, changes in its business relationships with independent agents who sell the Company's products, the Company's ability to retain key producing sales agents, the Company's ability to expand its distribution network, competitive factors such as the entrance of additional competitors into the Company's markets, competitive pricing practices, the Company's ability to generate new sales, sell new products and retain existing customers, the Company's ability to predict future health care cost trends and adequately price its products, and the Company's ability to control expenses during a time of declining revenue and membership.
- Federal and state health care reform laws adopted in recent years, currently proposed (such as the "Patients' Bill of Rights") or that may be proposed in the future, which affect or may affect the Company's operations, products, profitability or business prospects. Reform laws adopted in recent years generally limit the ability of insurers and health plans to use risk selection as a method of controlling costs for small group business.
- Regulatory factors, including delays in regulatory approvals of rate increases and policy forms; regulatory action resulting from market conduct activity and general administrative compliance with state and federal laws; restrictions on the ability of the Company's subsidiaries to transfer funds to the Company or its other subsidiaries in the form of cash dividends, loans or advances without prior approval or notification; the granting and revoking of licenses to transact business; the amount and type of investments that the Company may hold; minimum reserve and surplus requirements; and risk-based capital requirements.

15

- Factors related to the Company's efforts to deal with adverse medical loss ratio in its small group health business (which include implementing significant rate increases, terminating business in unprofitable markets, and introducing redesigned products), including the willingness of employers and individuals to accept rate increases, premium repricing and redesigned products.
- The development of and changes in claims reserves, particularly for highly regulated markets and exited markets where insureds may be inclined to increase utilization prior to termination of their policies.
- The effectiveness of the Company's strategy to expand sales of its MedOne products for individuals and families, to focus its small group health product sales in core markets and to grow its ancillary products, including its life, dental and self-funded benefit administration business.
- The cost and other effects of legal and administrative proceedings,

including the expense of investigating, litigating and settling any claims against the Company, and the general increase in litigation involving managed care and medical insurers.

- Adverse outcomes of litigation against the Company.
- Restrictions imposed by financing arrangements that limit the Company's ability to incur additional debt, pay future cash dividends and transfer assets.
- Changes in rating agency policies and practices and the ability of the Company's insurance subsidiaries to maintain or exceed their A- (Excellent) rating by A.M. Best.
- General economic conditions, including changes in employment, interest rates and inflation that may impact the performance on the Company's investment portfolio or decisions of individuals and employers to purchase the Company's products.
- The Company's ability to maintain attractive preferred provider networks for its insureds.
- The Company's ability to integrate effectively the operational, managerial and financial aspects of future acquisitions.
- Factors affecting the Company's ability to hire and retain key executive, managerial, professional and technical employees.
- Other business or investment considerations that may be disclosed from time to time in the Company's Securities and Exchange Commission filings or in other publicly disseminated written documents.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company's market risk has not substantially changed from the year ended December 31, 2000.

16

#### PART II. OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS

On August 26, 1999, a \$6.9 million verdict was entered against American Medical Security, Inc. ("AMS Inc."), the Company's third party administrator ("TPA") subsidiary, in the United States District Court for the Middle District of Alabama. The decision was made in a lawsuit brought against AMS Inc. by Skilstaf, Inc. ("Skilstaf"), an Alabama employee leasing company, in January 1998 alleging that AMS Inc. delayed claims payments under a contract with Skilstaf. Skilstaf sought unspecified damages. The contract, which was entered into in 1992 and terminated by Skilstaf in 1996, was a TPA contract for Skilstaf's self funded employee benefit plan. AMS Inc. has argued that this case is governed by the Employee Retirement Income Security Act of 1974, as amended, which preempts all state law causes of action and limits damages to contract damages. AMS Inc.'s post-trial motion to set aside the jury's finding was denied

by the court on March 20, 2000. As a result, AMS Inc. filed a notice of appeal with the Eleventh Circuit Federal Appeals Court on April 17, 2000. On March 12, 2001, the Company received the Court of Appeal's decision, rendered on March 9, 2001, affirming the decision of the District Court. On March 30, 2001, AMS Inc. filed a petition with the Court of Appeals for a rehearing by the full Court of Appeals, which was denied on May 4, 2001. On August 1, 2001, the Company filed a petition with the United States Supreme Court for a writ of certiorari to review the decision of the Court of Appeals. In July 2001, at the direction of the district court, the Company paid the full amount of the verdict plus interest. In October 2001, the United States Supreme Court denied the Company's writ of certiorari to review the Court of Appeals' decision. This case is now closed.

On February 7, 2000, a \$5.4 million verdict was entered against AMS Inc. and United Wisconsin Life Insurance Company ("UWLIC"), the Company's insurance subsidiary, in the Common Pleas Court of Delaware County, Ohio, Civil Division, in a lawsuit brought against AMS Inc. and UWLIC in 1996 by Health Administrators of America, Inc. ("Health Administrators"), an insurance agency owned and operated by a former agent of AMS Inc. The lawsuit alleges breach of written and oral contracts involving commission amounts and fraud. The case was heard and decided by a magistrate who awarded damages to Health Administrators, based on breach of written commission and agent contracts and ruled in favor of AMS Inc. and UWLIC on breach of oral contracts and fraud. On February 22, 2000, AMS Inc. and UWLIC filed objections with the Common Pleas Court requesting that the magistrate's decision against AMS Inc. and UWLIC be reversed. The Common Pleas Court approved the magistrate's decision on April 10, 2000. As a result, AMS Inc. and UWLIC filed a notice of appeal with the Court of Appeals, Delaware County, Ohio, Fifth Appellate District on April 18, 2000. On March 29, 2001, the Court of Appeals affirmed a portion of the verdict, with modifications, representing approximately \$3.0 million in damages, and reversed and remanded the remaining issues in the case representing approximately \$2.4 million in damages. On May 2, 2001, the Company appealed the \$3.0 million portion of the damages to the Ohio Supreme Court, which, on July 25, 2001, declined to take the appeal. Briefs have been submitted for the remanded portion of the case and the parties are awaiting the trial court's decision. Management believes the Company has adequately provided for losses that may result from this case.

The Company is involved in various other legal and regulatory matters occurring in the normal course of its business. While the ultimate outcome of the legal and regulatory matters cannot be determined at this time, in the opinion of management, adequate provision has been made for losses which may result from such matters; accordingly, the outcome of these matters is not expected to have a material adverse effect on the consolidated financial statements.

17

#### ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

On July 9, 2001, the Company issued 25,000 restricted shares of the Company's common stock ("Common Stock") to its Chief Executive Officer, Samuel V. Miller, in a private placement transaction without registration under the Securities Act of 1933, as amended, (the "Act") in reliance upon the exemption from registration provided by Section 4(2) of that Act. Consideration received by the Company for the shares consisted of the surrender for cancellation of nonqualified stock options granted to the Chief Executive Officer in 1995 and 1996 to purchase a total of 433,857 shares of Common Stock. The 25,000 shares, which were issued from the Company's treasury shares, are subject to forfeiture restrictions for a period of up to five years.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

#### (a) EXHIBITS

See the Exhibit Index following the Signature page of this report, which is incorporated herein by reference.

#### (b) REPORTS ON FORM 8-K

A Form 8-K dated August 9, 2001, was filed by the Company to report the adoption of a shareholder rights plan. A Form 8-K dated September 10, 2001, also was submitted by the Company to furnish Item 9, Regulation FD Disclosure, a financial presentation included on the Company's website.

18

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: NOVEMBER 13, 2001

AMERICAN MEDICAL SECURITY GROUP, INC.

/S/ GARY D. GUENGERICH
Gary D. Guengerich
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer and Chief
Accounting Officer and duly authorized to
sign on behalf of the Registrant)

19

AMERICAN MEDICAL SECURITY GROUP, INC. (COMMISSION FILE NO. 1-13154)

EXHIBIT INDEX

TO

FORM 10-Q QUARTERLY REPORT for quarter ended September 30, 2001

INCORPORATED HEREIN
BY REFERENCE TO

EXHIBIT NO. DESCRIPTION

3 Articles of Amendment to Restated Articles Exhibit 3 of the Registrant's Form 10

Incorporation with Respect to Designation, Preferences, Limitations and Relative Rights of Series B Junior Cumulative Preferred Stock.

for the quarter ended June 30, 2001.

Rights Agreement, dated as of August 9, Exhibit 1 to the 2001, between American Medical Security Registration Statement on Form 8-A fi Group, Inc. and Firstar Bank, N.A., as August 14, 2001 and Exhibit 4 to Rights Agents, including the form of Right Registrant's Current Report on Form Certificate as Exhibit B thereto.

Registran dated August 9, 2001, and filed August 14, 2001.

Restricted Stock Agreement with Chief 10 Executive Officer dated July 9, 2001.

EX-1